Wall Street’s Best Investments Daily Alert – 9/18/20
There are five holdings in this biotech fund.
Read More
biotech etf Archives
Daily Alert – 4/2/20
The top five holdings of this fund are Acceleron Pharma Inc (XLRN, 4.02% of assets), Momenta Pharmaceuticals Inc (MNTA, 3.99%), Ultragenyx Pharmaceutical Inc (RARE, 3.10%), Regeneron Pharmaceuticals Inc (REGN, 2.79%), and United Therapeutics Corp (UTHR, 2.71%).
Read More
What a Bernie Sanders Presidency Would Mean for the Stock Market
Worried about what a Bernie Sanders presidency would mean for the stock market? Or Elizabeth Warren? Or Joe Biden? Don't fret. Here's what you need to do.
Read More
This Options Barometer Tells You What the Hedge Funds Are Doing
In this topsy-turvy market, it helps to know how the big hedge funds and institutions are spending their money. This Options Barometer gives you the answer.
Read More
The Five Best ETFs of 2017
Identifying the best ETFs of 2017 is a good predictor of what sectors have plenty of momentum heading into 2018. Here are five that stood out.
Read More
How the Gilead-Kite Pharma Deal Is Driving Biotech Stocks
After two months of churn, biotech stocks are suddenly red-hot thanks to a blockbuster Gilead-Kite Pharma deal that's propping up the entire sector.
Read More
How to Choose the Best Pharma Stocks?
The best pharma stocks can be hard to find in a pharmaceutical industry rife with high-stakes conflicts over regulatory approvals, pricing and marketing.
Read More
Avoid This Biotech ETF for Pharma Stock Gains
Once a high riser, the IHE biotech ETF has been stuck in the mud for two years. But that doesn't mean you should tune out the biopharma industry as a whole.
Read More
Why Small Cap Stocks are Soaring after Trump Win
Stocks are rallying after Trump's win, but small cap stocks are outpacing them all. Here are three small cap sectors that are faring particularly well.
Read More
Three ETFs to Buy (and Two to Avoid) after Trump Win
Donald Trump's surprise victory has some ETFs soaring, and some crashing. Here are the funds you should buy, and which you should avoid, in the weeks ahead.
Read More
Insider Information and Options Trading
Insider trading is an unfortunate reality of the stock market, but options trading allows you to legally profit from some of these nefarious moves.
Read More
ETFs Continue Redemptions, but at a Slower Pace
Just received this information from yesterday’s Thomson Reuters Lipper report regarding fund inflows/outflows. It’s interesting to see which funds are being sold and which are attracting new money:
“For the second week in a row, equity ETFs witnessed net outflows; however, this past week handed...
Read More
Lean Bullish | Cabot Weekly Review
In this week’s Stock Market Video, Mike Cintolo discusses his "lean bullish" stance toward the market as the evidence continues to improve, especially when it comes to growth stocks—in fact, he's most impressed with the number of "liquid leaders" that have launched of usually...
Read More
How New Treatments are Fueling the Boom in Biotech Stocks
Biotech stocks have been red-hot this year, and a major reason for it is the glut of promising treatments being developed for diseases that have long been woefully undertreated.
Read More